METHODS AND COMPOSITIONS FOR USE OF CRL 5803 CELLS FOR EXPRESSION OF BIOTHERAPEUTICS AND ENCAPSULATED CELL-BASED DELIVERY
First Claim
1. A CRL 5803 cell genetically modified by transformation with one or more expression constructs, each construct comprising a nucleic acid encoding a transgene operatively linked to a promoter, wherein said cell expresses at least a first transgene, a second transgene, a third transgene and a fourth transgene,wherein at least one of said first, second, third or fourth transgenes encodes a therapeutic polypeptide andwherein said cell expresses said therapeutic polypeptide for at least 40 population doublings.
1 Assignment
0 Petitions
Accused Products
Abstract
The use of CRL 5803 cells as a robust cell substrate for transgene expression of polypeptides is contemplated. Furthermore, use of CRL 5803 cells in cell-based delivery and methods of making and using the same in encapsulated devices are contemplated.
90 Citations
56 Claims
-
1. A CRL 5803 cell genetically modified by transformation with one or more expression constructs, each construct comprising a nucleic acid encoding a transgene operatively linked to a promoter, wherein said cell expresses at least a first transgene, a second transgene, a third transgene and a fourth transgene,
wherein at least one of said first, second, third or fourth transgenes encodes a therapeutic polypeptide and wherein said cell expresses said therapeutic polypeptide for at least 40 population doublings.
- 9. A CRL 5803 cell deposited with DSMZ under accession number DSM ACC2730.
- 40. A human cell engineered with a cytosine deaminase expression construct derived from a wild-type cytosine deaminase bacterial gene sequence operably linked to a promoter element, wherein the cytosine deaminase expression construct expresses a protein comprising the amino acid sequence set forth in SEQ ID NO:
Specification